Improving patient selection for adjuvant therapy in high-risk renal cell carcinoma

Dylan M. Buller, Benjamin T. Ristau


From 2007 to 2011, the adjuvant sunitinib in high-risk renal cell carcinoma (RCC) after nephrectomy (S-TRAC) investigators conducted a phase 3, randomized, placebo-controlled trial with primary results published in 2016 (1). Patients with completely resected, high-risk RCC defined based on pathologic stage received either adjuvant sunitinib or placebo for a maximum of 1 year.